Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China.
10.3760/cma.j.cn112152-20210809-00597
- Collective Name:Tumor Pathology Committee of Chinese Anti-Cancer Association;Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology
- Publication Type:Journal Article
- Keywords:
Expert consensus;
Human epidermal growth factor receptor 2;
Testing;
Urothelial carcinoma
- MeSH:
Carcinoma, Transitional Cell/genetics*;
Consensus;
Humans;
Receptor, ErbB-2/genetics*;
Urinary Bladder Neoplasms/genetics*
- From:
Chinese Journal of Oncology
2021;43(10):1001-1006
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor 2 (HER-2) plays an important role in carcinogenesis and development of urothelial carcinoma. Overexpression of HER-2 is associated with poor prognosis of urothelial carcinoma. Although there is no significant benefit from anti-HER-2 targeted therapies of monoclonal antibody and tyrosine kinase inhibitor, Anti-HER-2 antibody-drug conjugate (HER-2-ADC) has shown a promising efficacy in urothelial carcinoma patients with HER-2 overexpression. Therefore, effectively screening the potential beneficiaries of HER-2-ADC drugs has become a new challenge. However, standardized HER-2 scoring system for urothelial carcinoma has yet to be developed. Thus, the Committees organized experts to reach this expert consensus based on the clinical practice of HER-2 expression, gene amplification and mutation testing in urothelial carcinoma, combined with the current research progress and internal discussion of committee members, in order to construct HER-2 testing standard of urothelial carcinoma and improve the accuracy of interpretation, to guide the clinical application.
